ROCKVILLE, Md., Jan. 23 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Penny Heaton, V.P., and Chief Medical Officer, will be presenting at the Phacilitate Vaccine Forum Washington 2009 conference on January 26, 2009 at the Grand Hyatt in Washington D.C. Dr. Heaton is participating in the Focus Session 'What benefits are single-use technologies and other novel vaccine manufacturing solutions providing in practice' and will be speaking to the Case Study: Virus-Like Particle (VLP) based vaccines for pandemic and seasonal influenza. Slides from the presentation will be posted on the Novavax website at www.novavax.com.
There are several reasons for utilizing virus-like particle technology as a vaccine platform. Recombinant technology permits tailoring of vaccines to contain only those proteins that are immunologically important for protection and structurally important for optimizing expression and yields. In addition, preclinical and clinical data have shown that VLPs activate multiple arms of the immune system, inducing robust humoral and cell-mediated immunity, which permits vaccine development for a wide range of disease targets. Further, VLPs may be more cost effective to produce because vaccines against different disease targets may be manufactured utilizing the same process and facility. Dr. Heaton's presentation will discuss these advantages, with a specific focus on the potential immunologic and manufacturing benefits of Novavax's pandemic and seasonal influenza VLP vaccines.
Novavax, Inc. (Nasdaq: NVAX) is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.
Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
|SOURCE Novavax, Inc.|
Copyright©2009 PR Newswire.
All rights reserved